← Pharmacy curriculum
Module 356 submodulesCurrent US prescribing information and contemporary HIT and VTE guidance

Parenteral Anticoagulants

Compare unfractionated heparin, low molecular weight heparins, fondaparinux, argatroban, and bivalirudin through target biology, dosing purpose, organ function, laboratory behavior, HIT risk, procedures, reversal, and transitions.

01

Classify parenteral anticoagulants by target, antithrombin dependence, route, clearance, monitoring, and reversal.

02

Initiate and monitor UFH while recognizing concentration errors, assay discordance, and heparin resistance.

03

Apply indication, weight, kidney function, pregnancy, administration, and neuraxial criteria to LMWH and fondaparinux.

04

Differentiate argatroban and bivalirudin use, monitoring, organ adjustment, and transition effects.

05

Assess suspected HIT with clinical probability and implement an immediate nonheparin anticoagulation pathway.

06

Manage bleeding, protamine use, procedures, neuraxial risk, and transitions without leaving an avoidable thrombosis gap.

35.01

Submodule

Targets and Clinical Selection

Injectable anticoagulants reach factor Xa or thrombin through antithrombin-dependent or direct mechanisms and differ in onset, persistence, clearance, monitoring, and HIT suitability.

What to learn
  • Antithrombin dependence
  • Anti-IIa and anti-Xa profiles
  • Direct thrombin inhibition
  • Clinical selection framework
Targets and dependenceParenteral anticoagulants differ by antithrombin dependence, factor selectivity, route, clearance, monitoring, and reversibility.
01UFHAntithrombin dependent

Inhibits thrombin and factor Xa

02LMWHAntithrombin dependent

Greater anti-Xa activity

03FondaparinuxAntithrombin dependent

Selective factor Xa inhibition

04Direct inhibitorsAntithrombin independent

Argatroban and bivalirudin inhibit thrombin

Use antithrombin as the first branch

UFH, LMWH, and fondaparinux bind antithrombin and accelerate inhibition of coagulation targets. Argatroban and bivalirudin bind thrombin directly without antithrombin. This distinction matters in antithrombin deficiency, HIT, laboratory interpretation, and agent selection.

Separate thrombin from factor Xa effects

UFH chains can support antithrombin inhibition of both factor Xa and thrombin. LMWH has relatively greater anti-Xa than anti-IIa activity. Fondaparinux selectively enhances antithrombin inhibition of factor Xa. Argatroban and bivalirudin directly inhibit thrombin.

Match kinetics to the clinical problem

UFH offers rapid titration and short persistence, which can help in unstable disease, severe renal dysfunction, or near-term procedures. LMWH provides more predictable subcutaneous exposure. Fondaparinux has prolonged renal elimination. Direct thrombin inhibitors support specific HIT and PCI pathways.

Plan the entire anticoagulation path

Indication and intensity determine whether the goal is prophylaxis, acute treatment, or procedural anticoagulation. Before the first dose, define monitoring, procedure timing, duration, transition, access, self-administration, and what will happen if bleeding or organ dysfunction develops.

Quick check

0 of 1 answered
01Which parenteral agent inhibits thrombin directly without requiring antithrombin?
Answer every question to submit.
35.02

Submodule

Unfractionated Heparin

UFH is rapidly titratable and reversible but combines concentration risk, variable binding, indication-specific protocols, laboratory limitations, resistance, and immune thrombocytopenia.

What to learn
  • Product and concentration safety
  • Weight-based initiation
  • aPTT and anti-Xa
  • Resistance and response failure
Unfractionated heparinUFH combines rapid titration and short persistence with variable binding, laboratory surveillance, concentration risk, and HIT potential.
01VerifyIndication and concentration

Separate treatment from flush products

02InitiateWeight-based protocol

Use the correct route and bolus

03MeasureaPTT or anti-Xa

Account for assay discordance

04RespondBleeding, resistance, or HIT

Reassess before escalating

Prevent concentration and route errors

Heparin products include multiple therapeutic concentrations and low-dose catheter solutions. Confirm total units, units per mL, total volume, route, container, pump library entry, and line before administration. UFH treatment is intravenous or subcutaneous and is not administered intramuscularly.

Initiate from the indication

Therapeutic UFH often uses a weight-based bolus and infusion, but intensity and bolus strategy differ for VTE, ACS, stroke, procedures, pregnancy, and high-bleeding-risk care. Use a validated current protocol and measured weight rather than copying a prior order.

Interpret aPTT and anti-Xa in context

aPTT is affected by reagent and patient factor biology. Heparin-calibrated anti-Xa testing can better reflect UFH activity in selected discordant states, yet residual oral factor Xa inhibitor, specimen interference, and antithrombin status can alter interpretation. Know the local assay.

Investigate resistance before escalation

Low laboratory response can reflect underdelivery, wrong weight, increased heparin-binding proteins, elevated factor VIII, antithrombin deficiency, assay discordance, or recent andexanet exposure. Confirm delivery and compare the clinically appropriate assays before repeated empiric dose escalation.

Quick check

0 of 1 answered
01What should happen first when a UFH aPTT remains unexpectedly low despite escalating doses?
Answer every question to submit.
35.03

Submodule

Low Molecular Weight Heparins

LMWH offers predictable subcutaneous therapy, but the regimen remains dependent on indication, dose intensity, kidney function, body weight, pregnancy, device technique, and neuraxial timing.

What to learn
  • Prophylaxis and treatment regimens
  • Renal and body-weight dosing
  • Selective anti-Xa monitoring
  • Self-injection and counseling
Low molecular weight heparinsLMWH provides more predictable subcutaneous exposure, but kidney function, body size, pregnancy, neuraxial timing, and indication still matter.
01SelectAgent and indication

Prophylaxis is not treatment

02CalculateWeight and renal function

Avoid unexamined dose caps

03AdministerSubcutaneous technique

Keep the air bubble when instructed

04MonitorCBC, kidney, bleeding

Use anti-Xa selectively

Separate prophylaxis from treatment

Fixed prophylaxis regimens reduce risk in defined medical and surgical settings, while established VTE treatment uses weight-based dosing. ACS, cancer-associated thrombosis, pregnancy, pediatric care, and perioperative bridging follow their own evidence and protocols.

Recalculate for renal and weight change

Enoxaparin exposure increases with severe renal impairment, and the labeled adjustment depends on the indication. Therapeutic regimens generally use actual body weight. Do not cap a dose automatically without a patient-specific evidence and monitoring plan.

Use anti-Xa selectively

Routine anti-Xa monitoring is unnecessary for most patients. It may help in selected pregnancy, extreme body size, renal dysfunction, pediatrics, recurrent thrombosis, or bleeding when a correctly timed result will change care. Use an LMWH-calibrated assay and a regimen-specific interpretation.

Teach the device, not just the dose

Demonstrate subcutaneous injection, site rotation, full dose delivery, handling of prefilled syringes and manufacturer-provided air bubbles, avoidance of rubbing, missed-dose instructions, bleeding signs, storage, and sharps disposal. Use return demonstration.

Quick check

0 of 1 answered
01Which statement about LMWH anti-Xa monitoring is most accurate?
Answer every question to submit.
35.04

Submodule

Fondaparinux

Fondaparinux is a synthetic selective indirect factor Xa inhibitor with once-daily subcutaneous use, prolonged renal clearance, weight-tiered VTE treatment, and distinct procedural limits.

What to learn
  • Synthetic pentasaccharide mechanism
  • Postoperative prophylaxis
  • Weight-tiered VTE treatment
  • Renal and neuraxial safety
FondaparinuxFondaparinux selectively enhances antithrombin inhibition of factor Xa and uses fixed prophylaxis or weight-tiered treatment dosing.
01TargetFactor Xa through antithrombin

No direct thrombin inhibition

02DoseIndication and body weight

Treatment uses weight tiers

03ClearPredominantly renal

Avoid severe renal impairment

04ProtectNeuraxial and bleeding safety

No routine protamine reversal

Inhibit factor Xa selectively

Fondaparinux reproduces the antithrombin-binding pentasaccharide sequence and enhances factor Xa inhibition. It does not directly inhibit thrombin and does not use the same molecular-size distribution as heparin or LMWH.

Delay prophylaxis until hemostasis

Postoperative prophylaxis uses a fixed dose and begins only after hemostasis is established and the labeled postoperative time requirement is met. Earlier administration increases bleeding risk. Low body weight and organ dysfunction require careful labeled review.

Use weight tiers for acute VTE

Adult acute DVT and PE treatment uses once-daily weight-tiered dosing. When transitioning to warfarin, overlap continues according to the treatment protocol until the required duration and INR criteria are met.

Respect renal persistence and procedure risk

Fondaparinux is eliminated mainly through the kidneys and is contraindicated in severe renal impairment under US labeling. Its persistence complicates urgent procedures and neuraxial care. Protamine does not provide established complete reversal.

Quick check

0 of 1 answered
01What is the most important dosing distinction for fondaparinux treatment of acute VTE?
Answer every question to submit.
35.05

Submodule

Parenteral Direct Thrombin Inhibitors

Argatroban and bivalirudin inhibit thrombin directly but occupy different HIT and PCI pathways and require different hepatic, renal, assay, and transition reasoning.

What to learn
  • Argatroban for HIT
  • Argatroban hepatic clearance and INR
  • Bivalirudin in PCI
  • Bivalirudin renal adjustment and ACT
Parenteral direct thrombin inhibitorsArgatroban and bivalirudin inhibit thrombin without antithrombin and occupy distinct HIT, PCI, hepatic, renal, and transition pathways.
01ArgatrobanHIT and PCI pathways

Hepatic clearance and INR effect

02BivalirudinPCI including HIT

Renal adjustment and ACT

03MonitoraPTT or ACT by use

Interpret with clinical context

04TransitionRestore durable therapy

Avoid unprotected gaps

Use argatroban for the HIT pathway

Argatroban is labeled for prophylaxis or treatment of thrombosis in adults with HIT and for PCI in adults with or at risk for HIT. It is titrated by aPTT outside PCI. Critical illness and hepatic dysfunction can substantially reduce dose requirements.

Account for hepatic clearance and INR

Argatroban depends mainly on hepatic clearance and needs a lower starting approach in hepatic impairment. It prolongs PT and INR, which complicates transition to warfarin. Follow an explicit algorithm rather than interpreting the combined INR as warfarin alone.

Use bivalirudin as a procedural anticoagulant

Bivalirudin is labeled for anticoagulation during PCI, including patients with HIT or HIT with thrombosis syndrome. The pathway uses a bolus and infusion with activated clotting time assessment and careful vascular-access and bleeding surveillance.

Adjust the bivalirudin infusion for kidney function

Renal dysfunction reduces bivalirudin clearance and requires labeled infusion adjustment, especially in dialysis. Review kidney function before PCI and during prolonged use. The PCI bolus and infusion are handled separately according to labeling.

Quick check

0 of 1 answered
01Why is warfarin transition from argatroban more complex than a simple INR threshold?
Answer every question to submit.
35.06

Submodule

Critical Safety and Transitions

Bleeding, HIT, neuraxial hematoma, protamine toxicity, pregnancy, organ change, and poorly timed transitions can rapidly outweigh the intended benefit of parenteral anticoagulation.

What to learn
  • Bleeding and protamine
  • HIT diagnosis and treatment
  • Neuraxial timing
  • Transitions and continuity
Critical safetyBleeding, neuraxial hematoma, HIT, protamine reactions, organ dysfunction, and transition errors require explicit prevention and response plans.
01BleedingStabilize and control source

Stop or reverse when appropriate

02HITUse 4Ts before testing

Stop all heparin and start nonheparin therapy

03NeuraxialCoordinate dose and catheter timing

Monitor neurologic symptoms

04TransitionDocument last and next dose

Protect against thrombosis gaps

Reverse heparin proportionally

Major bleeding requires stabilization and source control. Protamine neutralizes UFH and only partially reverses LMWH anti-Xa activity. Calculate from the heparin product, recent amount, route, and elapsed time. Administer slowly because protamine can cause severe hypotension, pulmonary reactions, and anaphylactoid events.

Treat HIT as thrombosis risk

Use the 4Ts score before laboratory testing. With intermediate or high probability, stop every heparin source and begin an appropriate nonheparin anticoagulant unless bleeding risk changes intensity. Order immunoassay and functional testing according to the diagnostic algorithm. Do not begin warfarin during acute HIT before platelet recovery.

Coordinate neuraxial care

Spinal or epidural hematoma can cause permanent paralysis. Use current anesthesia guidance and product labeling for the exact drug, prophylactic or therapeutic intensity, renal function, puncture, catheter removal, and restart. New back pain, weakness, numbness, or bladder and bowel dysfunction requires urgent evaluation.

Transition without overlap error or gaps

Write the current agent stop, next agent start, assay conditions, required overlap, organ criteria, and follow-up. Pregnancy, acute kidney or liver change, surgery, access loss, and recovery from HIT can all change the best destination therapy and timing.

Quick check

0 of 1 answered
01What is the immediate medication response to intermediate or high clinical probability of HIT?
Answer every question to submit.

Module test

Check the connections.

Each attempt draws 10 questions from the complete 112 question bank.

112 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

References

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. DailyMed. Heparin Sodium Injection Prescribing Information, revised 2026
  2. DailyMed. Enoxaparin Sodium Prescribing Information, updated 2026
  3. DailyMed. Fondaparinux Sodium Prescribing Information
  4. DailyMed. Argatroban Prescribing Information, updated 2026
  5. DailyMed. Bivalirudin Prescribing Information
  6. DailyMed. Protamine Sulfate Prescribing Information
  7. American Society of Hematology. Heparin-Induced Thrombocytopenia Guideline
PharmacyOpen tools